fromFast Company3 weeks agoWegovy and Zepbound prices are dropping, but steady access to the weight-loss drugs remains a challengePrices for Wegovy and Zepbound are decreasing, but access remains hindered by high costs and uneven insurance coverage.
Healthcarefromwww.theguardian.com2 months agoWho deserves weight-loss drugs? | David A KesslerThe American healthcare system fails to provide accessible medications and care, particularly for weight loss treatments.